Prothrombin Time Sensitivity and Specificity to Mild Clotting Factor Deficiencies of the Extrinsic Pathway: Evaluation of Eight Commercial Thromboplastins

Summary

Prothrombin-time (PT) sensitivity and specificity to mild clotting factor II, V, VII and X deficiencies have rarely been studied. We therefore carried out a prospective study, in 350 patients, of eight commercial thromboplastins (CTs) in their ability to detect mild clotting factor deficiencies, notably in factor VII. In each patient the factor II, V, VII and X clotting activities and PT performed with each CT were determined. For each CT, PT sensitivity and specificity in detecting factor deficiencies below 0.5 U/ml or below 0.4 U/ml were determined at various PTs, and then Receiver Operator Characteristic curves constructed. At optimum PT threshold level (sensitivity = specificity), exactitude varied from 0.64 to 0.74 (p < 0.01) and from 0.67 to 0.81 (p < 0.0001) in detecting deficiencies below 0.5 and 0.4 U/ml respectively. In conclusion, this study shows the limits of the PT test as performed with 8 CTs in patients with mild clotting factor deficiencies. The impact of such differences in sensitivity and specificity on monitoring certain patients subject to decrease in coagulation factor, and, in particular, of those under low-dose oral anticoagulant, remains to be determined.

• References

• 1 Kazama M, Suzuki S, Abe T, Tahara C, Shimazu C, Akiyama Y, Higashi K, Ishiguro I, Kimura T, Motoi S, Tsukai K, Kobayashi M, Niwa Y, Makita H, Yasumuro Y, Nakatake T. Evaluation of International Normalized Ratios by a controlled field survey with 4 different thromboplastin reagents. Thromb Haemost 1990; 64: 535-541
• 2 van den Besselaar AMHP. Multi-center study of replacement of the international reference preparation for thromboplastin, rabbit, plain. Thromb Haemost 1993; 70: 794-799
• 3 Caen J, Larrieu MJ, Samama M. L’Hemostase; Méthodes d’exploration et diagnostic pratique. Paris, Expansion Scientifique 1975
• 4 Bonvarlet MN, Pittet JL, Dupuy G, Aubry C. Evaluation of a new hypersensitive thromboplastin (bioMerieux) for the determination of prothrombin time. Blood 1992 80. 487a (Abstr.)
• 5 Rehemtulla A, Pepe M, Edgington TS. High level expression of recombinant human tissue factor in Chinese hamster ovary cells as a human thromboplastin. Thromb Haemost 1991; 65: 521-527
• 6 Tripodi A, Arbini A, Chantarangkul V, Mannucci PM. Recombinant tissue factor as substitute for conventional thromboplastin in the prothrombin time test. Thromb Haemost 1992; 67: 42-45
• 7 Roussi J, Drouet L, Samama M, Si’ P. French multicentric evaluation of recombinant tissue factor (Recombiplastin) for determination of prothrombin time. Thromb Haemost 1994; 72: 698-704
• 8 Kolde HJ, Hawkins P, Tejidor L, Denzler B, Ramirez I. Properties of a new thromboplastin reagent based on recombinant tissue factor and synthetic phospholipids. Klin Lab 1993; 39: 767-776
• 9 Hawkins P, Tejidor LP, Estevez R, Johnson K, Murza B, Maynard J, Lowrey D, Thorn R, Gaur P. Prothrombin time reagent prepared from recombinant human tissue factor produced in E. coli. Thromb Haemost 1991; 65: 1215
• 10 Bader R, Mannucci PMM, Tripodi A, Hirsh J, Keller F, Solleder EM, Hawkins P, Peng M, Pelzer H, Tejidor LM, Ramirez IF, Kolde HJ. Multicentric evaluation of a new PT reagent based on recombinant human tissue factor and synthetic phospholipids. Thromb Haemost 1994; 71: 292-299
• 11 Truchaud F, Cedou T, Fiks-Sigaud M, Bataille R, Truchaud A. Automatisa-tion des dosages chronomeétriques et chromogeniques en hemostase sur le système STA. Spectra Biol 1993; 5: 9-17
• 12 Pernod G, Bouabana B, Desrousseau B, Mossuz P, Drevait JM, Maljournal B, Rouhan D, Kolodié L, Polack B. A simultaneous evaluation of three multiparametric coagulation instruments: BFA®, Hemolab® and STA®. Nouv Rev Fr Hematol 1994; 36: 409-418
• 13 Metz CE. Basic principles of ROC analysis. Semin Nucl Med 1978; 8: 283-298
• 14 Bern MM, Lokich JJ, Wallach SR, Bothe A, Benotti PN, Arkin CF, Greco FA, Huberman M, Moore C. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 1990; 112: 423-428
• 15 Millenson MM, Bauer KA, Kistler JP, Barzegar S, Tulin L, Rosenberg RD. Monitoring “mini-intensit” anticoagulation with warfarin: Comparison of the prothrombin time using a sensitive thromboplastin with prothrombin fragment Fl+2 levels. Blood 1992; 79: 2034-2038
• 16 Hawkins P, Doobay H, Tejidor L, Johnson K, Peng M, Pelzer H, Kolde HJ, Ramirez I, Gaur P. The international normalized ratio and factor sensitivity of a prothrombin time reagent based on recombinant human tissue factor. Thromb Haemost 1993; 69: 662
• 17 Me Vay PA, Troy PTCY. Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities. Transfusion 1991; 31: 164-171
• 18 Poggio M, Tripodi A, Mariani G, Mannucci PM. Factor VII clotting assay: influence of different thromboplastins and factor VH-deficient plasmas. Thromb Haemost 1991; 65: 160-164
• 19 Kitchen S, Preston FE. Factor VII clotting assays: influence of thromboplastin. Thromb Haemost 1993 70. 720 (Letter)